COCP READ THE FULL COCP RESEARCH REPORT Business Update Multiple Upcoming Catalysts Cocrystal Pharma, Inc. (NASDAQ:COCP) has multiple upcoming catalysts over the next few months as it develops ...

The National Institutes of Health (NIH) has unveiled a new artificial intelligence (AI) algorithm designed to more ...

The World Institute of Kimchi(WIKIM) has announced that the regular consumption of kimchi, a traditional Korean fermented ...

A recent discussion with BDO's clinical trials editor and Audrey Davis of CSC, discussed strategies to increase clinical ...

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

Barbara O’Brien, MD, discusses the background behind the phase 2 TBCRC049 study investigating the combination of tucatinib, trastuzumab, and capecitabine for the treatment of patients with ...

Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.

A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular ...

Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...